Ragweed-SPIRE Follow-On Study
NCT02396680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249
Last updated 2016-03-23
Summary
The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.
Conditions
- Rhinoconjunctivitis
- Ragweed Allergy
Sponsors & Collaborators
-
Adiga Life Sciences, Inc.
collaborator INDUSTRY -
Circassia Limited
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-30
- Primary Completion
- 2016-02-29
Countries
- Canada
Study Locations
More Related Trials
-
ToleroMune Grass Follow on Study
NCT02292875 ·Status: COMPLETED
-
Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis
NCT00325338 ·Status: COMPLETED ·Phase: PHASE2
-
ToleroMune Ragweed Exposure Chamber Study
NCT01198613 ·Status: COMPLETED ·Phase: PHASE2
-
Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy
NCT01361412 ·Status: COMPLETED ·Phase: PHASE2
-
A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season
NCT00982163 ·Status: COMPLETED
-
Efficacy and Safety of Grass-SPIRE Registration Study
NCT02795273 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Ragweed Observational Study
NCT01398137 ·Status: COMPLETED
-
A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)
NCT01469182 ·Status: COMPLETED ·Phase: PHASE3
-
ToleroMune Grass Follow on Study
NCT01923779 ·Status: COMPLETED
-
Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy
NCT00110786 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
NCT03038971 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies
NCT00599872 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
NCT00671268 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy
NCT00293904 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of AL-53817 Nasal Spray Solution
NCT01454505 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study in Adults Sensitized to Short Ragweed
NCT00670384 ·Status: WITHDRAWN ·Phase: PHASE2
-
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
NCT00258635 ·Status: COMPLETED ·Phase: PHASE2
-
ToleroMune Grass Exposure Unit Study
NCT01385800 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever
NCT01500629 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
NCT02478398 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis
NCT01166061 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
NCT02601690 ·Status: TERMINATED
-
Safety and Efficacy of SPARC1203 in Allergic Rhinitis
NCT01614691 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
NCT04881461 ·Status: COMPLETED ·Phase: PHASE3
-
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
NCT03558997 ·Status: COMPLETED ·Phase: PHASE2